Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine
Moderna (MRNA) and Merck (MRK) have reported significant clinical success with intismeran, a personalized cancer vaccine. When used in combination with Merck's Keytruda, the vaccine reduced the risk of death and melanoma recurrence by 42% in late-stage trials. This development offers Moderna a potential long-term growth catalyst beyond its COVID-19 vaccine revenue. However, the personalized nature of the treatment presents significant scalability hurdles. The manufacturing process requires approximately six weeks to customize for individual patients, which limits economies of scale and likely results in high production costs. While analysts project peak annual sales could exceed $5 billion for melanoma alone, these logistical complexities may impact overall profitability and the speed at which Moderna can return to positive earnings.
Topics: biotechnology cancer vaccine clinical trials melanoma treatment